Carboplatin-based Nanomedicine to Enhance the Anticancer Effect in SK-NEP-1 WilmsꞌTumor Cells

@article{Ming2017CarboplatinbasedNT,
  title={Carboplatin-based Nanomedicine to Enhance the Anticancer Effect in SK-NEP-1 WilmsꞌTumor Cells},
  author={Ming Ming and Z. Ma and Yong-tao Xu and Feng-yin Sun and Xin-hai Cui},
  journal={Iranian Journal of Pharmaceutical Research : IJPR},
  year={2017},
  volume={16},
  pages={1305 - 1311}
}
  • Ming Ming, Z. Ma, +2 authors Xin-hai Cui
  • Published 2017
  • Chemistry, Medicine
  • Iranian Journal of Pharmaceutical Research : IJPR
    • Wilms tumor (WT) is the most common pediatric malignant primary renal tumor. Carboplatin (CRB), a platinum compound is widely used in the treatment of multiple cancers including ovarian, lung, head and neck, and wilm’s tumor. However, lower uptake of CRB in cancer cells and toxicity concerns in healthy cells often limited its clinical outcome. The aim of this study was to investigate the antitumor effect of CRB on SK-NEP-1 wilm’s cancer cells. Earlier, CRB was formulated in nanoparticulate… CONTINUE READING
    View on PubMed
    ijpr.sbmu.ac.ir

    References

    SHOWING 1-10 OF 20 REFERENCES
    Encapsulation in Nanoparticles Improves Anti-cancer Efficacy of Carboplatin
    • 33
    • PDF
    Role of Carboplatin in the Treatment of Triple Negative Early- Stage Breast Cancer.
    • 9
    Current challenges in Wilms' tumor management
    • 41
    In vivo pharmacokinetics, biodistribution and antitumor effect of paclitaxel-loaded micelles based on α-tocopherol succinate-modified chitosan
    • 13
    Favorable Response of Heavily Treated Wilms’ Tumor to Paclitaxel and Carboplatin
    • 2
    Therapeutic efficacy of paclitaxel and carboplatin via arterial or venous perfusion in rabbits with VX-2 tongue cancer.
    • 2
    • PDF
    Correlation of tumor-associated macrophages and clinicopathological factors in Wilms tumor
    • 11
    • PDF
    SK‐NEP‐1 and Rh1 are Ewing family tumor lines
    • 59
    Wilms' tumor
    • 235
    Redox-responsive polymer-drug conjugates based on doxorubicin and chitosan oligosaccharide-g-stearic acid for cancer therapy.
    • 77